Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
About
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Enabling Technologies and Transformative Platforms initiative will support needed to rigorously validate transformative, multi-use platforms or technologies that can enable. Well-suited applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention or epidemiology. Proposed platforms and technologies may have widespread applicability but must be able to improve the outlook for HLBS-related diseases and disorders.
The Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research grant is designed for researchers and organizations seeking to bridge the gap between basic science discoveries and clinical applications in heart, lung, blood, and sleep (HLBS) diseases. This National Heart, Lung, and Blood Institute (NHLBI) program provides comprehensive support to validate innovative, multi-use platforms and technologies that can accelerate progress in early detection, screening, diagnosis, treatment, and prevention of HLBS-related conditions. The R33 mechanism specifically supports the validation phase of research, excluding clinical trials. Eligible applicants include HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian serving institutions, tribal governments, faith-based and community-based organizations, and eligible federal agencies. Researchers and entrepreneurs should apply if they have transformative platform technologies with widespread applicability that can significantly improve outcomes for HLBS diseases. This grant supports the development of translational researchers skilled in product development and entrepreneurship, making it ideal for teams ready to move their innovations toward commercialization and human testing. Funding supports rigorous validation of technologies that demonstrate potential to transform multiple aspects of disease management and prevention.
Funding Facts
● Applications openDeadline
December 23, 2027
Award Amount
Up to $350K
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Grant Amount
Up to $350K
Deadline
2027-12-23
Grant Type
federal
Application Cycle
Annual - Deadline December 23, 2027
Best For
Research institutions, HBCUs, minority-serving institutions, and organizations developing innovative diagnostic and therapeutic platform technologies for HLBS diseases
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Govern
Frequently Asked Questions
Who is eligible for Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)?
Eligible applicants include Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Alaska Native and Native Hawaiian serving institutions, Indian/Native American tribal governments, faith-based and community-based organizations, and eligible federal agencies. For complete eligibility requirements and institutional details, consult the official NHLBI announcement.
How much funding does Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) provide?
Funding ranges from up to $350,000 for this grant cycle. Actual amounts may vary depending on the scope of proposed research and specific program guidelines. Check the official NHLBI website for the most current funding information.
How do I apply for Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)?
Applications are submitted through the standard federal grant application process. Visit the official NHLBI Catalyze program website and grants.nih.gov for detailed application instructions, required forms, submission deadlines, and guidance on preparing your proposal. Ensure your application addresses the validation of your enabling technology or transformative platform.
What can Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) funding be used for?
Funding supports rigorous validation of innovative, multi-use platforms and technologies applicable to heart, lung, blood, and sleep disease research. Eligible uses include research and development for early detection, screening, model development, clinical diagnosis, treatment, control, behavior modification, prevention, and epidemiology. The R33 mechanism specifically focuses on the validation phase, excluding clinical trial conduct. Projects must demonstrate potential to significantly accelerate or transform HLBS-related disease management.
Last updated: July 5, 2026